These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1085 related articles for article (PubMed ID: 26547265)

  • 1. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
    Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
    EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in the treatment of Kawasaki disease.
    Weng KP; Ou SF; Lin CC; Hsieh KS
    J Chin Med Assoc; 2011 Nov; 74(11):481-4. PubMed ID: 22100015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of acute and refractory Kawasaki disease.
    Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
    Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
    Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
    PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
    Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
    Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revisiting the role of steroids and aspirin in the management of acute Kawasaki disease.
    Dhanrajani A; Yeung RSM
    Curr Opin Rheumatol; 2017 Sep; 29(5):547-552. PubMed ID: 28661936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
    Wooditch AC; Aronoff SC
    Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kawasaki disease: part II. Complications and treatment.
    Bayers S; Shulman ST; Paller AS
    J Am Acad Dermatol; 2013 Oct; 69(4):513.e1-8; quiz 521-2. PubMed ID: 24034380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the treatment of Kawasaki disease.
    Dominguez SR; Anderson MS
    Curr Opin Pediatr; 2013 Feb; 25(1):103-9. PubMed ID: 23283289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN; Anderson MS; Mulvahill MJ; Heizer H; Glodé MP; Dominguez SR
    Pediatr Infect Dis J; 2018 Oct; 37(10):976-980. PubMed ID: 29461447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroids for the treatment of Kawasaki disease in children.
    Wardle AJ; Connolly GM; Seager MJ; Tulloh RM
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011188. PubMed ID: 28129459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
    Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
    Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
    Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Kawasaki disease: what you need to know].
    Bajolle F; Laux D
    Arch Pediatr; 2012 Nov; 19(11):1264-8. PubMed ID: 22921712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
    Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
    JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.
    Newburger JW; Takahashi M; Gerber MA; Gewitz MH; Tani LY; Burns JC; Shulman ST; Bolger AF; Ferrieri P; Baltimore RS; Wilson WR; Baddour LM; Levison ME; Pallasch TJ; Falace DA; Taubert KA;
    Pediatrics; 2004 Dec; 114(6):1708-33. PubMed ID: 15574639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.
    Newburger JW; Takahashi M; Gerber MA; Gewitz MH; Tani LY; Burns JC; Shulman ST; Bolger AF; Ferrieri P; Baltimore RS; Wilson WR; Baddour LM; Levison ME; Pallasch TJ; Falace DA; Taubert KA; ; ; ;
    Circulation; 2004 Oct; 110(17):2747-71. PubMed ID: 15505111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant herbal therapy for targeting susceptibility genes to Kawasaki disease: An overview of epidemiology, pathogenesis, diagnosis and pharmacological treatment of Kawasaki disease.
    Tang B; Lo HH; Lei C; U KI; Hsiao WW; Guo X; Bai J; Wong VK; Law BY
    Phytomedicine; 2020 Apr; 70():153208. PubMed ID: 32283413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.